Amgen’s Vectibix Wins EU Approval to Treat Metastatic Colorectal Cancer

The European Medicines Agency has approved a new use of Amgen’s Vectibix as first-line treatment in combination with Folfiri chemotherapy for metastatic colorectal cancer, the drugmaker said.

Vectibix (panitumumab) is indicated for adult patients with wild-type RAS mCRC. Folfiri, an irinotecan-based chemotherapy regimen, is frequently used in first-line colorectal cancer treatment in Europe.

Vectibix also is approved in the EU as a second-line treatment for adult patients with WT RAS mCRC in combination with Folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan) and as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. — Jonathon Shacat